Earth Science Tech, Inc. (ETST) Caps a Year of Achievement by Doubling Revenues
- Portfolio of hemp-derived CBD products
- Opening of new production facilities
- New subsidiaries, acquisitions and joint ventures
Earth Science Tech, Inc. (OTC: ETST) is celebrating another year of accomplishment. In 2017, the company churned out a series of advancements that included the launch of new subsidiaries and products and an acquisition, along with entry into marketing, manufacturing and distribution agreements. It also commenced pre-launch human trials of a new product designed to join the fight against opioid addiction. As a result, 2017 revenues were almost twice as much as in 2016. Now, even though the stock is trading at around $1.00, a price target of over $4.00 has been set.
Earth Science is making waves in the hemp-derived cannabinoid (CBD), nutraceutical, pharmaceutical and medical device markets. The company’s activities range from R&D to production to marketing and distribution. It continues to build the networks and infrastructure to launch new products, embarking on a number of joint ventures and acquisitions, and launching new subsidiaries. It has created a new division, Cannabis Therapeutic Inc., to develop proprietary cannabinoid-based nutraceuticals and pharmaceutical products based on its existing CBD patent.
The company also acquired Canna Inno Laboratories Inc., which will allow it access to Canadian government grants. Grant applications have already been filed, and the company anticipates that its first request will be approved in Q1 2018. Earth Science expects that, through this new subsidiary, about half of all R&D expenditures will be covered by grants. A joint venture with Karmavore SuperFood is set to manufacture a new chocolate product, and one with Varsity Group, LLC, a kanna ingredient based e-liquid company, will give Earth Science a presence in the recreational vape/smoke market. Kanna, widely consumed in South Africa, is thought to decrease anxiety.
With these platforms in place, the ETST pipeline is filled with goodies like the CBD Organic Chocolate line and the Strawberry Orange Blossom CBD oil, as well as a pet CBD oil. Earth Science also plans to create two new cannabinoid-based pharmaceutical drugs and three new advanced cannabinoid-based nutraceutical products in collaboration with Smart Medicine, Inc. an independent laboratory based at Le Centre Québecois d’Innovation en Biotechnologie (“CQIB”) in Laval, Québec. In addition, Earth Science is developing proprietary prophylactic therapies to prevent breast cancer, and a treatment to help women with aggressive breast cancer. Additionally, seizing on an opportunity to enter the recreational vape/smoke market, the company launched a new wholly-owned subsidiary, KannaBidioid Inc., in its joint venture with Varsity Group, LLC, to manufacture and distribute vapes/e-liquids and gummy edibles.
In 2017, new manufacturing and shipping facilities were opened. Earth Science commenced leasing a manufacturing facility for the production of the MSN-2 medical device and began the first round of negotiations with foreign health authorities for commercialization of the product. MSN-2, designed to protect women and their future babies from chlamydia, will be launched in 2018 in select countries. In addition, ETST signed an agreement with the Centre de Développement Bioalimentaire du Québec (“CDBQ”), a major force in the agro-food industry in Canada. Based in La Pocatière, Quebec, CDBQ specializes in helping companies develop the processes needed to take a prototype agro-food or nutraceutical product to industrial-scale production for the marketplace. CDBQ boasts a bio-food incubator, which encompasses a 30,000 square foot, $10 million facility that houses seven separate factories equipped with cutting-edge equipment and technology.
Earth Science is also working with the Clinique SIDA Amité (AIDS Friendship Clinic) to conduct an amini-clinical trial, the last trial needed before the MSN-2 device enters molecular diagnostic trials. The company has started pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD oil mixed with a known natural ingredient proven to help increase dopamine levels.
The hemp-derived CBD market is projected to grow at a CAGR of about 53 percent until 2020, positioning it as the fastest-growing sub-segment within the multi-billion dollar legal cannabis and hemp market. With an eye on that expanding market, ETST plans to launch a Regulation A+ Tier 2 round of financing in 2018. The goal will be to raise $4 million to complete all planned projects.
For more information, visit the company’s website at www.EarthScienceTech.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Portfolio of hemp-derived CBD products
- Opening of new production facilities
- New subsidiaries, acquisitions and joint ventures
Earth Science Tech, Inc. (OTC: ETST) is celebrating another year of accomplishment. In 2017, the company churned out a series of advancements that included the launch of new subsidiaries and products and an acquisition, along with entry into marketing, manufacturing and distribution agreements. It also commenced pre-launch human trials of a new product designed to join the fight against opioid addiction. As a result, 2017 revenues were almost twice as much as in 2016. Now, even though the stock is trading at around $1.00, a price target of over $4.00 has been set.
Earth Science is making waves in the hemp-derived cannabinoid (CBD), nutraceutical, pharmaceutical and medical device markets. The company’s activities range from R&D to production to marketing and distribution. It continues to build the networks and infrastructure to launch new products, embarking on a number of joint ventures and acquisitions, and launching new subsidiaries. It has created a new division, Cannabis Therapeutic Inc., to develop proprietary cannabinoid-based nutraceuticals and pharmaceutical products based on its existing CBD patent.
The company also acquired Canna Inno Laboratories Inc., which will allow it access to Canadian government grants. Grant applications have already been filed, and the company anticipates that its first request will be approved in Q1 2018. Earth Science expects that, through this new subsidiary, about half of all R&D expenditures will be covered by grants. A joint venture with Karmavore SuperFood is set to manufacture a new chocolate product, and one with Varsity Group, LLC, a kanna ingredient based e-liquid company, will give Earth Science a presence in the recreational vape/smoke market. Kanna, widely consumed in South Africa, is thought to decrease anxiety.
With these platforms in place, the ETST pipeline is filled with goodies like the CBD Organic Chocolate line and the Strawberry Orange Blossom CBD oil, as well as a pet CBD oil. Earth Science also plans to create two new cannabinoid-based pharmaceutical drugs and three new advanced cannabinoid-based nutraceutical products in collaboration with Smart Medicine, Inc. an independent laboratory based at Le Centre Québecois d’Innovation en Biotechnologie (“CQIB”) in Laval, Québec. In addition, Earth Science is developing proprietary prophylactic therapies to prevent breast cancer, and a treatment to help women with aggressive breast cancer. Additionally, seizing on an opportunity to enter the recreational vape/smoke market, the company launched a new wholly-owned subsidiary, KannaBidioid Inc., in its joint venture with Varsity Group, LLC, to manufacture and distribute vapes/e-liquids and gummy edibles.
In 2017, new manufacturing and shipping facilities were opened. Earth Science commenced leasing a manufacturing facility for the production of the MSN-2 medical device and began the first round of negotiations with foreign health authorities for commercialization of the product. MSN-2, designed to protect women and their future babies from chlamydia, will be launched in 2018 in select countries. In addition, ETST signed an agreement with the Centre de Développement Bioalimentaire du Québec (“CDBQ”), a major force in the agro-food industry in Canada. Based in La Pocatière, Quebec, CDBQ specializes in helping companies develop the processes needed to take a prototype agro-food or nutraceutical product to industrial-scale production for the marketplace. CDBQ boasts a bio-food incubator, which encompasses a 30,000 square foot, $10 million facility that houses seven separate factories equipped with cutting-edge equipment and technology.
Earth Science is also working with the Clinique SIDA Amité (AIDS Friendship Clinic) to conduct an amini-clinical trial, the last trial needed before the MSN-2 device enters molecular diagnostic trials. The company has started pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD oil mixed with a known natural ingredient proven to help increase dopamine levels.
The hemp-derived CBD market is projected to grow at a CAGR of about 53 percent until 2020, positioning it as the fastest-growing sub-segment within the multi-billion dollar legal cannabis and hemp market. With an eye on that expanding market, ETST plans to launch a Regulation A+ Tier 2 round of financing in 2018. The goal will be to raise $4 million to complete all planned projects.
For more information, visit the company’s website at www.EarthScienceTech.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
